PI
CMPX icon

Pennant Investors’s Compass Therapeutics CMPX Stock Holding History

Pennant Investors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-199,000
Closed -$199K – 26
2024
Q2 		$199K Hold
199,000
– – 0.05% 37
2024
Q1 		$394K Hold
199,000
– – 0.1% 31
2023
Q4 		$310K Buy
+199,000
New +$344K 0.07% 37

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Pennant Investors's CMPX Position: Q3 2024 in Review

Pennant Investors sold out of Compass Therapeutics (CMPX) in Q3 2024, closing a stake of 199,000 shares — an estimated $199K sold.

Pennant Investors first reported a position in CMPX in Q4 2023 and held it in 3 quarters. The position peaked at $394K in Q1 2024. 79 funds tracked by Wall St. Rank hold CMPX as of Q3 2024.

  • Pennant Investors reported no remaining Compass Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 199,000 Compass Therapeutics shares in Q3 2024, an estimated $199K.
  • Pennant Investors first reported a position in Compass Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Compass Therapeutics position peaked at $394K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.